 |
 |
 |
||||||||||||||
|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
||||
| < 2005 News Listings | ||||||||||||||||
|
New York, NY January 4, 2005 Rho Ventures is pleased to announce that Claudio Bertuccioli has been promoted to Principal. Dr. Bertuccioli has been with Rho for over three years as an Associate, focusing primarily on healthcare and biotechnology investments. Prior to joining Rho in 2001, Dr. Bertuccioli was with Atlas Venture and with Oliver, Wyman & Co. Dr. Bertuccioli holds a B.A. from Cambridge University and a Ph.D. from the Rockefeller University in Molecular Biology and Genetics. Rho Ventures is a venture capital firm with extensive investments in the healthcare, information technology and communication sectors. Since it was founded in 1981, the firm has invested in over 150 venture stage companies and helped build market leaders across many high growth industries. Previous investments include Active Power, Capstone Turbine, Ciena Corporation, Commerce One, Compaq Computer Corporation, Copper Mountain, Inc., Diversa Corporation, Human Genome Sciences, Inc., iVillage, Leukosite (currently part of Millenium Pharmaceuticals), MedImmune, Inc., NitroMed, Senomyx, Tercica, Tripod (currently part of Lycos) and Vicuron. More information on Rho can be found at www.rho.com. |
|
|
Copyright ©2007 Rho Capital Partners, Inc.